用于治疗新型冠状病毒肺炎的血管紧张素受体阻滞剂：关于正在进行及未来前瞻性临床试验的病理生理学和药理学考量
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials.
作者信息
Rothlin Rodolfo Pedro, Duarte Mariano, Pelorosso Facundo Germán, Nicolosi Liliana, Salgado M Victoria, Vetulli Héctor Miguel, Spitzer Eduardo
机构信息
Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina, Buenos Aires, Argentina.
Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
出版信息
Front Pharmacol. 2021 Mar 29;12:603736. doi: 10.3389/fphar.2021.603736. eCollection 2021.
Abstract
COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotensin II-driven lung inflammation. This has triggered several prospective clinical trials. In this commentary we provide an overview and analysis of current ongoing clinical trials aimed at evaluating the therapeutic efficacy of angiotensin receptor blocker (ARB) use in COVID-19. The relevance of the results of these trials will have to be interpreted depending on the stage and severity of the disease and in light of the start time of their prescription related to the time of diagnosis of COVID-19 as well as the administered doses.
摘要
新冠疫情需要迅速做出反应，以找到能有效降低发病率和死亡率的治疗手段。尽管最初令人担忧，但回顾性观察研究的证据支持抑制肾素-血管紧张素系统，这是延缓或减轻血管紧张素II驱动的肺部炎症的一条新途径。这引发了多项前瞻性临床试验。在这篇评论中，我们概述并分析了当前正在进行的旨在评估血管紧张素受体阻滞剂（ARB）用于治疗新冠疗效的临床试验。这些试验结果的相关性将必须根据疾病的阶段和严重程度，以及与新冠诊断时间相关的用药开始时间和给药剂量来解读。
相似文献
1
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials.用于治疗新型冠状病毒肺炎的血管紧张素受体阻滞剂：关于正在进行及未来前瞻性临床试验的病理生理学和药理学考量
Front Pharmacol. 2021 Mar 29;12:603736. doi: 10.3389/fphar.2021.603736. eCollection 2021.
2
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?肾素-血管紧张素系统抑制对靶器官保护的作用：我们能否做得更好？
Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.
3
Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.通过抑制肾素-血管紧张素系统预防2型糖尿病
Drugs. 2004;64(22):2537-65. doi: 10.2165/00003495-200464220-00004.
4
Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂治疗 COVID-19：一项随机临床试验的实时系统评价。
Medwave. 2021 Mar 3;21(2):e8105. doi: 10.5867/medwave.2021.02.8105.
5
Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.替米沙坦（一种市售的血管紧张素II 1型受体阻滞剂）的胰岛素增敏特性在预防心房颤动发生中的作用。
Med Hypotheses. 2006;66(1):118-20. doi: 10.1016/j.mehy.2005.07.018. Epub 2005 Sep 12.
6
Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.血管紧张素受体阻滞剂（ARB）/钙通道阻滞剂与 HCTZ 的联合用药与 HCTZ 最大推荐剂量的 ARB 相比在 2 期高血压患者中的应用：依福地平与缬沙坦治疗 2 期收缩期高血压（EXALT）研究。
J Clin Hypertens (Greenwich). 2011 Aug;13(8):588-97. doi: 10.1111/j.1751-7176.2011.00492.x. Epub 2011 Jul 14.
7
8
Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms.血管紧张素 II 型 1 型受体在腹主动脉瘤中的致病和治疗意义。
Curr Drug Targets. 2018;19(11):1318-1326. doi: 10.2174/1389450119666180122155642.
9
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.血管紧张素转换酶抑制剂、血管紧张素Ⅱ1型受体拮抗剂，还是两者联用？基于ONTARGET研究结果发表后一位临床药理学家的观点。
Ther Adv Cardiovasc Dis. 2008 Aug;2(4):233-48. doi: 10.1177/1753944708094309.
引用本文的文献
1
Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era.新型冠状病毒2型相关心肌纤维化的可能机制：大流行后时代的思考
Front Microbiol. 2024 Oct 8;15:1470953. doi: 10.3389/fmicb.2024.1470953. eCollection 2024.
2
Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19.基于文献的发现以阐明难治性高血压与2019冠状病毒病之间的生物学联系
Biology (Basel). 2023 Sep 21;12(9):1269. doi: 10.3390/biology12091269.
3
Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.血管紧张素 II 在心血管疾病中的作用：双沙坦作为 2019 年冠状病毒新型治疗方法的介绍。
Biomolecules. 2023 May 2;13(5):787. doi: 10.3390/biom13050787.
4
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.细胞色素 P450 2C9 在 COVID-19 治疗中的作用：现状与未来方向。
Eur J Drug Metab Pharmacokinet. 2023 May;48(3):221-240. doi: 10.1007/s13318-023-00826-8. Epub 2023 Apr 24.
5
Lung Injury in COVID-19 Has Pulmonary Edema as an Important Component and Treatment with Furosemide and Negative Fluid Balance (NEGBAL) Decreases Mortality.新型冠状病毒肺炎中的肺损伤以肺水肿为重要组成部分，使用呋塞米和负液体平衡（NEGBAL）治疗可降低死亡率。
J Clin Med. 2023 Feb 15;12(4):1542. doi: 10.3390/jcm12041542.
6
Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections.用于治疗 COVID-19 肺病和其他呼吸道感染的替米沙坦纳米混悬剂。
Mol Pharm. 2023 Jan 2;20(1):750-757. doi: 10.1021/acs.molpharmaceut.2c00448. Epub 2022 Nov 30.
7
Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.血管紧张素转化酶抑制剂和血管紧张素受体拮抗剂治疗新型冠状病毒肺炎有效性和安全性的系统评价和 Meta 分析
J Am Heart Assoc. 2022 Sep 6;11(17):e026143. doi: 10.1161/JAHA.122.026143. Epub 2022 Aug 24.
8
Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.血管紧张素 II 型受体（AT1R）：通向 COVID-19 相关疾病的大门。
Molecules. 2022 Mar 22;27(7):2048. doi: 10.3390/molecules27072048.
9
Does the Serum Concentration of Angiotensin II Type 1 Receptor Have an Effect on the Severity of COVID-19? A Prospective Preliminary Observational Study among Healthcare Professionals.血管紧张素II 1型受体的血清浓度对新型冠状病毒肺炎的严重程度有影响吗？一项针对医护人员的前瞻性初步观察性研究。
J Clin Med. 2022 Mar 23;11(7):1769. doi: 10.3390/jcm11071769.
10
Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy-effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker.5/6 肾切除大鼠肾脏和心脏中 SARS-CoV-2 宿主因子的调节-盐、ARB、DPP4 抑制剂和 SGLT2 阻滞剂的作用。
BMC Nephrol. 2022 Mar 24;23(1):117. doi: 10.1186/s12882-022-02747-1.
本文引用的文献
1
Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial.替米沙坦治疗新冠肺炎患者：一项开放的多中心随机临床试验。
EClinicalMedicine. 2021 Jun 18;37:100962. doi: 10.1016/j.eclinm.2021.100962. eCollection 2021 Jul.
2
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 合并高血压患者住院和死亡风险的关系。
J Am Heart Assoc. 2021 Jul 6;10(13):e018086. doi: 10.1161/JAHA.120.018086. Epub 2021 Feb 24.
3
SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells.SARS-CoV-2 刺突蛋白通过激活上皮细胞中的血管紧张素 II 受体信号促进 IL-6 转信号。
PLoS Pathog. 2020 Dec 7;16(12):e1009128. doi: 10.1371/journal.ppat.1009128. eCollection 2020 Dec.
4
Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.比较肾素-血管紧张素-醛固酮系统阻滞剂治疗下合并和不合并 SARS-CoV-2 肺部感染患者的感染风险和临床结局：系统评价和荟萃分析。
Br J Clin Pharmacol. 2021 Jun;87(6):2475-2492. doi: 10.1111/bcp.14660. Epub 2020 Dec 18.
5
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.血浆醛固酮和C反应蛋白水平与新型冠状病毒肺炎的严重程度：Dyhor-19研究
J Clin Med. 2020 Jul 21;9(7):2315. doi: 10.3390/jcm9072315.
6
Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.PRAETORIAN-COVID 试验的原理和设计：一项双盲、安慰剂对照随机临床试验，使用缬沙坦预防 SARS-CoV-2 感染疾病住院患者的急性呼吸窘迫综合征。
Am Heart J. 2020 Aug;226:60-68. doi: 10.1016/j.ahj.2020.05.010. Epub 2020 May 21.
7
Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.评估肾素-血管紧张素-醛固酮系统（RAAS）抑制剂对 COVID-19 结局的影响：一项荟萃分析。
J Infect. 2020 Aug;81(2):276-281. doi: 10.1016/j.jinf.2020.05.052. Epub 2020 May 28.
8
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
9
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
10
Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.替米沙坦作为血管紧张素受体阻滞剂治疗 COVID-19 的初步尝试。
Drug Dev Res. 2020 Nov;81(7):768-770. doi: 10.1002/ddr.21679. Epub 2020 May 1.
Zotero 插件